Last reviewed · How we verify
STI-1558
STI-1558 is a small molecule drug that targets the SGLT2 receptor.
STI-1558 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | STI-1558 |
|---|---|
| Also known as | An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro). |
| Sponsor | Zhejiang ACEA Pharmaceutical Co. Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
STI-1558 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine and decreased glucose levels in the blood. By targeting SGLT2, STI-1558 aims to improve glycemic control in patients with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) (PHASE3)
- A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects (PHASE1)
- [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects (PHASE1)
- A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558 (PHASE1)
- Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients (PHASE1)
- Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |